Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8345883 | 0.86 | ALDH1A1 (0.30) | ALDH1A1ALOX15TSHR | |
| SCHEMBL697284 | 0.69 | — | — | |
| SCHEMBL21834512 | 0.67 | — | — | |
| SCHEMBL11039510 | 0.65 | — | — | |
| SCHEMBL12355745 | 0.65 | — | — | |
| SCHEMBL11462771 | 0.61 | — | — | |
| SCHEMBL20711402 | 0.60 | LMNA (0.34) | — | |
| SCHEMBL21725827 | 0.60 | — | — | |
| SCHEMBL10511473 | 0.57 | GLP1R (0.31) | — | |
| SCHEMBL1332087 | 0.51 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | claimed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | claimed |
| EP-3094619-B1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | MASSACHUSETTS GEN HOSPITAL (US) | 2019-07-31 | — | — | EP | claimed |
| EP-3094619-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2016-11-23 | — | — | EP | claimed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | claimed |
| WO-2015106240-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION (US) | 2015-07-16 | — | — | WO | claimed |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | disclosed |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | THE GENERAL HOSPITAL CORPORATION (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3626707-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | The General Hospital Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3094619-B1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | MASSACHUSETTS GEN HOSPITAL (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| WO-2015106240-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331782-A1 | HETEROARYL DISULFIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR INCREASING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | HIF1AN, HBG2, HIF1A | FBP1 1435/4885ALDH1A1 2214/4885ALOX15 1005/4885 |
| US-10758569-B2 | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin | HIF1AN, HBG2, HIF1A | FBP1 1435/4885ALDH1A1 2214/4885ALOX15 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.